Elanco

Elanco, a US-based pharmaceutical preparation manufacturing company, reported its 2025 greenhouse gas emissions as:

• Scope 1: 181,624,000 kg CO2e
• Scope 2 (market-based): 303,364,000 kg CO2e
• Scope 3: 513,589,000 kg CO2e

For 2024, Elanco's emissions were:

• Scope 1: 175,807,000 kg CO2e
• Scope 2 (market-based): 302,607,000 kg CO2e
• Scope 3: 496,505,000 kg CO2e

In 2023, Elanco's emissions were:

• Scope 1: 145,021,000 kg CO2e
• Scope 2 (market-based): 285,188,000 kg CO2e
• Scope 3: 655,353,000 kg CO2e

Elanco is committed to several climate initiatives:

• Net-zero for Hook office: Achieve net zero Scope 1 and 2 greenhouse gas emissions for its Hook office by 2030.
• UK and Ireland fleet: Eliminate internal combustion engine vehicles from the UK and Ireland affiliate's fleet by 2030.
• Renewable electricity: Aims to purchase renewable electricity equal to 100% of its electricity consumption by 2030, contributing to a 100% reduction in Scope 1 and Scope 2 emissions.
• Customer emissions avoidance: Through its products and services, Elanco aims to help its customers avoid 21 million metric tons of greenhouse gas emissions by 2030, using a 2020 base year.

Elanco's net-zero commitment has been validated by the Science Based Targets initiative (SBTi) with a long-term target year of 2050 for all scopes.